Literature DB >> 19574837

Expression of CRM1 in human gliomas and its significance in p27 expression and clinical prognosis.

Aiguo Shen1, Yuchan Wang, Yueming Zhao, Lin Zou, Linlin Sun, Chun Cheng.   

Abstract

OBJECTIVE: Gliomas are the most common type of primary intracranial tumor. Although tumor grade predicts the clinical course of most patients, molecular characteristics of individual tumors have emerged as important prognostic factors for patients with gliomas. Reduced expression of p27 protein is known as an independent prognostic marker in a large variety of cancers and is associated with an unfavorable prognosis. It is believed that phosphorylation of p27 on Ser10 has been shown to be required for the binding of CRM1, a carrier protein for nuclear export. This study assessed whether CRM1, Ser10-phosphorylated p27, and p27 correlated with each other, with glioma pathological stage, and with patient outcome.
METHODS: Immunohistochemical and Western blot analysis were performed in 70 cases of human gliomas and normal brain tissues. Survival analyses were performed using the Kaplan-Meier method.
RESULTS: High CRM1 expression (80% of cancer cell nuclei stained) was observed in 70 specimens and was related to the grade of malignancy. A strong inverse correlation was evident between p27 levels and both Ser10-phosphorylated p27 (P < 0.001) and CRM1 level (P < 0.001). We also reviewed each grade of tumors separately and investigated whether CRM1 expression predicted patient survival within each subgroup. In brief, CRM1 overexpression was significantly associated with overall survival (P < 0.001).
CONCLUSION: The current results showed that CRM1 and p27 expression were associated with glioma grade and that high CRM1 protein expression might be related to poor outcome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19574837     DOI: 10.1227/01.NEU.0000348550.47441.4B

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  90 in total

1.  Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.

Authors:  Adam L Green; Shakti H Ramkissoon; Dilara McCauley; Kristen Jones; Jennifer A Perry; Jessie Hao-Ru Hsu; Lori A Ramkissoon; Cecile L Maire; Benjamin Hubbell-Engler; David S Knoff; Sharon Shacham; Keith L Ligon; Andrew L Kung
Journal:  Neuro Oncol       Date:  2014-11-02       Impact factor: 12.300

2.  CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas.

Authors:  Fang Zhou; Wensheng Qiu; Ruyong Yao; Jinyu Xiang; Xiaoxiao Sun; Shihai Liu; Jing Lv; Lu Yue
Journal:  Med Oncol       Date:  2013-09-12       Impact factor: 3.064

3.  Importin 7 and exportin 1 link c-Myc and p53 to regulation of ribosomal biogenesis.

Authors:  Lior Golomb; Debora Rosa Bublik; Sylvia Wilder; Reinat Nevo; Vladimir Kiss; Kristina Grabusic; Sinisa Volarevic; Moshe Oren
Journal:  Mol Cell       Date:  2012-01-27       Impact factor: 17.970

4.  Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy.

Authors:  Paul M Tyler; Mariah M Servos; Romy C de Vries; Boris Klebanov; Trinayan Kashyap; Sharon Sacham; Yosef Landesman; Michael Dougan; Stephanie K Dougan
Journal:  Mol Cancer Ther       Date:  2017-02-01       Impact factor: 6.261

5.  XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.

Authors:  Parvathi Ranganathan; Trinayan Kashyap; Xueyan Yu; Xiaomei Meng; Tzung-Huei Lai; Betina McNeil; Bhavana Bhatnagar; Sharon Shacham; Michael Kauffman; Adrienne M Dorrance; William Blum; Deepa Sampath; Yosef Landesman; Ramiro Garzon
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

6.  Adhesion to fibronectin induces p27(Kip1) nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-mediated drug resistance (CAM-DR) in RPMI 8,226 cells.

Authors:  Min Fei; Qinglei Hang; Sicong Hou; Songbin He; Changgeng Ruan
Journal:  Mol Cell Biochem       Date:  2013-10-30       Impact factor: 3.396

Review 7.  Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.

Authors:  Jo Ishizawa; Kensuke Kojima; Numsen Hail; Yoko Tabe; Michael Andreeff
Journal:  Pharmacol Ther       Date:  2015-06-03       Impact factor: 12.310

8.  Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.

Authors:  Rosa Lapalombella; Qingxiang Sun; Katie Williams; Larissa Tangeman; Shruti Jha; Yiming Zhong; Virginia Goettl; Emilia Mahoney; Caroline Berglund; Sneha Gupta; Alicia Farmer; Rajeswaran Mani; Amy J Johnson; David Lucas; Xiaokui Mo; Dirk Daelemans; Vincent Sandanayaka; Sharon Shechter; Dilara McCauley; Sharon Shacham; Michael Kauffman; Yuh Min Chook; John C Byrd
Journal:  Blood       Date:  2012-10-03       Impact factor: 22.113

Review 9.  Aiding and abetting cancer: mRNA export and the nuclear pore.

Authors:  Biljana Culjkovic-Kraljacic; Katherine L B Borden
Journal:  Trends Cell Biol       Date:  2013-04-10       Impact factor: 20.808

10.  Upregulation of CRM1 relates to neuronal apoptosis after traumatic brain injury in adult rats.

Authors:  Aihong Li; Feihui Zou; Hongran Fu; Gang Cui; Yaohua Yan; Qiyun Wu; Xingxing Gu
Journal:  J Mol Neurosci       Date:  2013-03-15       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.